Article Figures & Data
Figures
- FIGURE 1.
Ultraviolet (UV, 260 nm) SE HPLC profiles of uncoupled, native cMORF (A) and MAG3-coupled cMORF (B) and radioactivity profile of 99mTc-labeled MAG3-cMORF (C).
- FIGURE 2.
Ultraviolet (UV, 260 nm) SE HPLC profile of MN14-MORF (A), radioactivity profiles of labeled cMORF added to MN14-MORF at weight ratios of 0.04 μg/25 μg (B) and 0.25 μg/25 μg (C), and radioactivity profile of labeled cMORF added to native MN14 as control (D). Extent of labeled cMORF binding decreased as weight of labeled cMORF increased.
- FIGURE 3.
Plot of data from saturation study shows variation in ratio of free labeled cMORF to labeled cMORF-MN14-MORF as increasing weights of labeled cMORF were added. Curve was extrapolated to origin to estimate average number of MORF groups per MN14 molecule.
- FIGURE 4.
Radioactivity SE HPLC profiles of urine obtained at 3 h from control mouse receiving only labeled cMORF (A) and from study mouse receiving both MN14-MORF and labeled cMORF (B) and radiochromatograms, on same axes, of plasma obtained at 3 h from control mouse (C) and from study mouse (D). Results show that radioactivity in urine was present primarily as labeled cMORF, whereas in plasma, significant levels of radioactivity were present only in study mice and then only as labeled cMORF-MN14-MORF.
- FIGURE 5.
Gamma camera images of LS174T tumor-bearing nude mice show whole-body anterior views obtained at 3 h (A) and 24 h (C) and, during repeated study after removal of urine, at 3 h (B). In each pair of images, study animal is on left and control animal is on right.
Tables
Site 0.5 h 1.0 h 3.0 h Mean SD Mean SD Mean SD Organ (%ID/g) Liver 0.23 0.06 0.15 0.02 0.15 0.04 Heart 0.22 0.07 0.07 0.01 0.04 0.01 Kidneys 6.10 0.75 7.10 0.57 6.40 1.02 Lungs 0.42 0.09 0.15 0.02 0.07 0.01 Spleen 0.16 0.02 0.10 0.02 0.09 0.02 Muscle 0.17 0.04 0.09 0.07 0.02 0.01 Blood 0.74 0.18 0.18 0.05 0.04 0.01 Whole body (%ID) 22.50 4.40 11.70 2.30 7.00 1.00 %ID = percentage injected dose.
Site 3 h 24 h Control Study Control Study Mean SD Mean SD Mean SD Mean SD Organ (%ID/g) Liver 0.23 0.01 0.41 0.05 0.10 0.01 0.60 0.05 Heart 0.04 0.01 0.18 0.01 0.02 0.00 0.13 0.02 Kidneys 6.40 1.95 6.90 1.96 3.20 0.68 4.00 1.00 Lungs 0.07 0.01 0.34 0.06 0.04 0.01 0.24 0.04 Spleen 0.11 0.01 0.29 0.08 0.07 0.01 0.31 0.04 Muscle 0.03 0.03 0.09 0.01 0.02 0.00 0.07 0.01 Tumor 0.09 0.01 1.80 0.24 0.05 0.00 1.70 0.14 Blood 0.04 0.01 1.02 0.13 0.00 0.01 0.50 0.12 Whole body (%ID) 6.90 3.30 14.40 0.90 5.00 2.00 11.40 0.70
In this issue
Jump to section
Related Articles
Cited By...
- Pretargeted Imaging and Therapy
- Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting
- Diels-Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody
- Auger Radiation-Induced, Antisense-Mediated Cytotoxicity of Tumor Cells Using a 3-Component Streptavidin-Delivery Nanoparticle with 111In
- An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector
- Successful Radiotherapy of Tumor in Pretargeted Mice by 188Re-Radiolabeled Phosphorodiamidate Morpholino Oligomer, a Synthetic DNA Analogue.
- Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
- Amplification Targeting: A Modified Pretargeting Approach with Potential for Signal Amplification--Proof of a Concept